Skip to content
Peptide research

Chonluten

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A synthetic tripeptide marketed as a bioregulator for bronchial mucosal support and anti-inflammatory, antioxidant action. The case is almost entirely preclinical and mechanism-only, randomized human trials remain unverified, and nearly all research traces to one lab with no independent replication. Long-term human safety is unknown. Not an approved drug in the US, and unregulated products sold online are of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Chonluten is a synthetic peptide made of just three amino acids, developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. It is derived from bronchial (lung airway) tissue and is designed to support respiratory health by regulating gene expression related to inflammation, antioxidant defense, and cell renewal in the lungs and airways.

How it works in the body

A bioregulator tripeptide (Glu-Asp-Gly) that targets respiratory epithelial cells. It enters these cells and interacts with gene promoter regions to regulate the expression of proteins involved in mucosal immune defense, surfactant production, and airway tissue maintenance.

Research overview

Chonluten is theorized to work by entering cell nuclei and directly interacting with DNA to turn down genes involved in inflammation and oxidative stress while supporting healthy cell turnover in lung tissue. Lab studies using immune cells showed that Chonluten reduces production of TNF (a key inflammatory signal), decreases immune cell attachment to blood vessel walls, and modifies cellular signaling patterns associated with inflammation. It is closely related to Bronchogen, another short peptide that targets overlapping airway-related genes. The evidence base is very limited: it consists primarily of cell culture and animal studies, with most research originating from a single Russian group. No randomized controlled human clinical trials have been published in Western peer-reviewed journals.

Who researches Chonluten?

Commonly researched by

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching respiratory health

    Studied for effects on lung function, bronchial health, or respiratory tissue.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(8)

Rated by level of concern

  • Human evidence is limited to weak developer reports; randomized clinical benefit remains unconfirmed.

    High

    Absence-of-evidence finding: no ClinicalTrials.gov records and no controlled-trial publications located for Chonluten / Glu-Asp-Gly

  • Almost all research originates from a single group (Khavinson / St. Petersburg Institute of Bioregulation and Gerontology) — no independent replication

    High

    PMID 35408963 (originating-group authorship on the main 'independent' study); author survey of the EDG literature

  • Long-term safety profile in humans is unknown

    Moderate

    Absence-of-evidence finding: no PK or toxicology studies located for EDG

  • Potential allergic reactions or individual intolerance

    Low

    Class-level expectation for peptide preparations; no Chonluten-specific adverse-event literature located

  • Contraindicated during pregnancy and lactation (per manufacturer)

    Low

    Manufacturer labeling for Khavinson-derived bioregulator products (non-regulatory); no reproductive toxicology located

  • Quality varies among unregulated products sold online — no pharmaceutical-grade standardization

    Moderate

    Regulatory status: no FDA-approved product and no USP monograph for Chonluten/EDG

  • Increased apoptosis observed in vitro (Avolio et al. 2022) — implications for healthy tissue unclear

    Low

    Avolio et al., Int J Mol Sci 2022;23(7):3607 (PMID 35408963)

  • Gene expression modulation effects on pre-existing conditions (e.g., cancer) are unstudied

    Theoretical

    PMC7583759 (claimed gene targets, review-level); PMID 35408963 (proliferation/apoptosis endpoints); no oncology data located

Interaction summary(8)

Rated by direction with this peptide

  • Anti-TNF and anti-IL-6 biologics (e.g., adalimumab, infliximab, tocilizumab)

    CautionTheoretical

    Chonluten suppressed LPS-induced pro-inflammatory cytokine release (including TNF-alpha and IL-6) in human macrophages in vitro, so using it with a cytokine-blocking biologic could in principle add to immunosuppression. No in vivo, pharmacokinetic, or human interaction data exist; this is mechanistic overlap only.

    Avolio et al., Int J Mol Sci 2022;23(7):3607 (PMID 35408963); no interaction studies exist

  • Systemic and inhaled corticosteroids (prednisone, budesonide, fluticasone)

    CautionTheoretical

    These are the drugs Chonluten is most likely to be taken alongside in COPD or asthma. The shared anti-inflammatory direction is additive only in theory; the concrete hazard is behavioral — a user reducing prescribed steroid therapy on the strength of an unproven peptide.

    Mechanistic overlap per PMID 35408963; no interaction studies published

  • Active cytotoxic chemotherapy or a history of malignancy

    CautionTheoretical

    EDG is claimed at review level to modulate c-Fos, HSP70 and COX-2, and it has never been studied in any tumor model or oncology population, so effects in the presence of cancer are unpredictable in either direction. No pharmacokinetic interaction with chemotherapeutics is known or expected; the caution is about the unstudied biology, not drug-level interference.

    PMC7583759 (claimed gene targets, review-level); PMID 35408963; no oncology data located

  • Immunosuppressants after transplant (tacrolimus, cyclosporine, mycophenolate)

    CautionTheoretical

    Any agent with reported immune-modulating activity and no pharmacokinetic or safety data should not be added to a transplant regimen where immune balance is tightly titrated. This is a precautionary inference, not a documented interaction.

    Mechanistic inference from PMID 35408963; no clinical or PK data

  • Bronchogen (AEDL/ADEL tetrapeptide)

    SynergisticTheoretical

    Both are marketed by the same group for respiratory indications and their claimed gene targets are described as complementary. The combination has never been tested in a controlled study; claims about joint use in chronic bronchitis/COPD come from non-indexed Russian review material rather than trial data.

    PMC7583759 (originating-group review); Khavinson group AEDL work (Lung, 2014)

  • Other Khavinson bioregulators (Thymalin, Thymogen, Epitalon, Vilon)

    CautionTheoretical

    Several Khavinson short peptides were compared side by side in the same human macrophage model with broadly overlapping cytokine suppression, so using them together plausibly compounds immune modulation, including Chonluten's reported pro-apoptotic effect, with no combination safety data and no demonstrated benefit. Additive immunosuppression without evidence of benefit is a caution, not a synergy.

    Avolio et al., Int J Mol Sci 2022;23(7):3607 (PMID 35408963); no combination studies exist

  • Bronchodilators (LABA/LAMA, albuterol, tiotropium)

    NeutralTheoretical

    No shared receptor, metabolic pathway, or reported clinical interaction; a tripeptide with likely negligible systemic persistence is not expected to affect beta-agonist or antimuscarinic pharmacology. As with steroids, the practical caution is not substituting an unproven peptide for prescribed rescue or maintenance therapy.

    No interaction data located in PubMed or product labeling

  • Antioxidant supplements (N-acetylcysteine, vitamin E)

    NeutralTheoretical

    Chonluten is claimed — at review level only, with no primary data — to upregulate endogenous antioxidant enzymes such as SOD rather than act as a direct radical scavenger, so overlap with exogenous antioxidants is conceptual at most and no additive or antagonistic effect has been demonstrated.

    Khavinson group review, Molecules 2020 (PMC7583759) — review-level claim, no primary EDG data

Known risks(8)

  • Human evidence is limited to weak developer reports; randomized clinical benefit remains unconfirmed.

  • Almost all research originates from a single group (Khavinson / St. Petersburg Institute of Bioregulation and Gerontology) — no independent replication

  • Long-term safety profile in humans is unknown

  • Potential allergic reactions or individual intolerance

  • Contraindicated during pregnancy and lactation (per manufacturer)

  • Quality varies among unregulated products sold online — no pharmaceutical-grade standardization

  • Increased apoptosis observed in vitro (Avolio et al. 2022) — implications for healthy tissue unclear

  • Gene expression modulation effects on pre-existing conditions (e.g., cancer) are unstudied

Drug interactions(4)

  • Bronchogen (AEDL)

    Both target respiratory tissue via related but distinct mechanisms. Sometimes used in combination in Russian bioregulator protocols. No formal interaction studies.

  • Epithalon

    Both are Khavinson bioregulatory peptides. Epithalon targets telomerase/pineal; Chonluten targets bronchial. Sometimes co-administered in Russian anti-aging protocols. No interaction data.

  • Immunosuppressants

    Chonluten modulates inflammatory cytokines (TNF-alpha). Potential for unpredictable interactions with immunosuppressive therapy. No data available.

  • NSAIDs / Corticosteroids

    Both Chonluten and NSAIDs/corticosteroids modulate COX-2 and inflammatory pathways. Potential additive or antagonistic effects. No formal studies.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
5
Human Studies
42

Evidence consists primarily of one well-designed in vitro study (Avolio et al. 2022, IJMS) using THP-1 monocytic cells, plus preclinical animal studies and mechanistic investigations from Khavinson's group. Most claims about bronchial mucosal support derive from the broader Khavinson bioregulatory peptide framework rather than Chonluten-specific clinical trials. The related tetrapeptide Bronchogen (AEDL) has more published data on bronchial gene expression. Evidence is limited and predominantly from a single research group.

Researched for(5)

Rated by confidence in the evidence

  • Anti-inflammatory modulation

    Low

    Reduced TNF-alpha and IL-6 release in one human immune cell study, not independently replicated.

    Avolio et al., Int J Mol Sci 2022;23(7):3607 (PMID 35408963) — primary in vitro source; Khavinson group review on peptides and COVID-19, Molecules 2020 (PMC7583759) — review-level, originating group

  • Bronchial mucosal support

    Speculative

    Based on a developer comparison with standard-treatment controls; randomization was not reported and benefit remains unconfirmed.

    Khavinson et al., "Peptides: Prospects for Use in the Treatment of COVID-19," Molecules (2020), PMC7583759 (review-level). This peer-reviewed review states oral EDG tripeptide (Chonluten's own sequence, Glu-Asp-Gly) "enhanced the effectiveness of standard therapy in patients with chronic bronchitis with an asthmatic component": a clinical comparison with standard-treatment controls; randomization was not reported. The work is from the Khavinson group, with no independent replication.

  • Antioxidant gene regulation

    Speculative

    Mentioned only in review articles; no primary study has measured this effect directly.

    Khavinson group review, Molecules 2020 (PMC7583759) — review citing internal, non-indexed work; no primary source located

  • Gene expression modulation

    Speculative

    DNA-binding, gene-regulation data exist for related peptides like Bronchogen and Epitalon, not Chonluten itself.

    PMID 35408963 (Chonluten tested directly, but only protein/functional endpoints: MAPK phosphorylation, TNF output in THP-1 cells, not gene expression). Gene-expression attribution for Chonluten/EDG appears only in the originating group's own review, PMC7583759, not in independent primary data. The Khavinson/Popovich systematic review (Molecules 2021, 26(22), 7053) documents DNA-binding and gene-expression evidence for other Khavinson peptides (Bronchogen/AEDL, Epitalon/AEDG, Pinealon/EDR, Vilon/KE) and does not mention Chonluten/EDG.

  • Respiratory tissue regeneration

    Speculative

    Extrapolated from a different peptide; the cited cell-line experiment found increased cell death, not repair.

    PMID 35408963 (apoptosis finding); AEDL/Bronchogen lung work (Khavinson group, Lung 2014) — different molecule, extrapolated

Benefits(5)

  • Anti-inflammatory modulation

  • Bronchial mucosal support

  • Antioxidant gene regulation

  • Gene expression modulation

  • Respiratory tissue regeneration

Key studies(3)

  1. Avolio F, Martinotti S, Khavinson VK, et al.

    International Journal of Molecular Sciences

    2022

    Chonluten (designated P5 in study) reduced TNF production in LPS-stimulated THP-1 monocytes, downregulated monocyte adhesion to endothelial cells, modulated tyrosine phosphorylation, and appeared to increase apoptosis levels. Concentration used: 100 ng/mL. Suggests anti-inflammatory TNF tolerance mechanism.

  2. Khavinson VKh, Tendler SM, Vanyushin BF, et al.

    Lung

    2014

    Studied related tetrapeptide AEDL (Bronchogen) in bronchial epithelial cells. Demonstrated regulation of Ki67, Mcl-1, p53, NOS-3 proteins and activation of MUC4, MUC5AC, SFTPA1 genes. AEDL binds DNA at guanine N7 sites. Establishes framework for Khavinson bronchial peptide bioregulation. Note: This study examines AEDL/Bronchogen, not EDG/Chonluten directly.

  3. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR

    Molecules

    2021

    Systematic review of Khavinson peptide bioregulator framework. Describes how short peptides (2-7 amino acids) penetrate nuclei, interact with histones and DNA, and regulate tissue-specific gene transcription. Covers broader class including bronchial peptides. Note: Reviews AEDL bronchial data; EDG/Chonluten not individually profiled.

Regulation & availability

Why researchers look at it

Cell studies show this Khavinson bioregulator peptide reduces TNF production and immune cell adhesion — two key drivers of chronic airway inflammation — by acting at the gene level. Evidence comes mainly from the developer group and collaborators, with no verified randomized human trials, but if independent replication confirms the bronchial gene-regulation effects, Chonluten could become relevant for respiratory anti-aging.

Estimated cost
$30-80/mo oral capsules
FDA status
Chonluten is not FDA-approved and is not eligible for compounding in the US.
WADA status
Not explicitly listed on WADA Prohibited List. However, peptide bioregulators as a class may fall under S0 (Non-Approved Substances) depending on interpretation. Athletes should consult anti-doping authorities.
Prescribability
Research only (March 2026). Not FDA-approved. Not scheduled under FDA peptide categories. No US compounding pathway exists for Chonluten.
Availability
Not available through US compounding pharmacies. Not prescription-regulated in most jurisdictions.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(4)

  1. 1990s-2000s
    DevelopmentSynthesized by Prof. Vladimir Khavinson and team at St. Petersburg Institute of Bioregulation and Gerontology as part of broader bioregulatory peptide program.
  2. 2000s
    Russian marketIntroduced commercially in Russia as part of Cytogen dietary supplement line by GARMONIA Ltd.
  3. 2022
    Key publicationAvolio et al. published first detailed in vitro mechanistic study in International Journal of Molecular Sciences (PMID: 35408963).
  4. 2026-03
    Current statusNot FDA-approved. Not found in the reviewed FDA 503A or 503B nomination categories. Marketed internationally as a supplement in some jurisdictions. IND and NDA filing status are not publicly confirmed.

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

What is Chonluten?

Chonluten is a synthetic tripeptide (Glu-Asp-Gly) bioregulator developed by Prof. Vladimir Khavinson, designed to target lung and bronchial mucosal tissue. It belongs to the Cytogen class of synthesized peptide bioregulators.

How does Chonluten differ from Bronchogen?

Chonluten (EDG, tripeptide) and Bronchogen (AEDL, tetrapeptide) both target respiratory tissue but have different amino acid compositions. Bronchogen has more published research on bronchial gene expression.

Is there clinical evidence for Chonluten?

Evidence is limited. One well-designed in vitro study (Avolio et al. 2022) demonstrated anti-inflammatory effects in THP-1 monocytes. No published randomized controlled human clinical trials exist in Western peer-reviewed journals. Most claims extrapolate from the broader Khavinson peptide framework.

Is Chonluten safe?

No serious adverse effects have been reported in available literature, but human safety data is extremely limited. Contraindications include individual intolerance, pregnancy, and lactation. Long-term safety in humans is unknown.

Can Chonluten be prescribed in the US?

No. Chonluten is not FDA-approved and is not available through US pharmacies or compounding pharmacies.